Saturday, May 3, 2025

11:30 AM - 12:15 PM

Grand Ballroom

---

Overview

Prof Sepehr Sakib

---

Details

This session will focus on DOAC dosing, addressing common issues with underdosing and the clinical consequences. We will explore the clinical reasoning behind selecting specific DOACs and the indications for combining antiplatelet and anticoagulant therapies. Additionally, the session will cover the role of SGLT2 inhibitors in heart failure treatment, examining their potential benefits and risks. This comprehensive discussion will enhance understanding of optimal dosing and therapy choices to improve patient outcomes in clinical practice. Learning objectives: 1. Identify common issues with underdosing of DOACS and their clinical consequences. 2. Discuss clinical reasons for DOAC choices. 3. Identify indications for combined antiplatelet and anticoagulant therapy. 4. Describe the potential benefits and risks of SGLT2 inhibitors for heart failure. Competency standards (2016): 3.1, 3.3, 3.5

---

Speaker